Doctors News Hubb
Advertisement Banner
  • Home
  • News
  • Healthcare
  • Public Health
  • Paramedic
  • Nursing
  • Contact Us
No Result
View All Result
  • Home
  • News
  • Healthcare
  • Public Health
  • Paramedic
  • Nursing
  • Contact Us
No Result
View All Result
Doctors News Hubb
No Result
View All Result
Home News

Efficacy and Safety of Tenecteplase in Wake-up Stroke Patients by Non-contrast CT (TWIST)

admin by admin
February 14, 2023
in News


The following is a summary of the “Safety and efficacy of tenecteplase in patients with wake-up stroke assessed by non-contrast CT (TWIST): a multicentre, open-label, randomized controlled trial,” published in the February 2023 issue of Neurology by Roaldsen, et al.


Clinical guidelines and current evidence both advocate intravenous thrombolysis with alteplase for patients with wake-up stroke who have been identified for treatment using magnetic resonance imaging or perfusion imaging. However, there is typically a lack of availability for high-tech imaging methods. Researchers wanted to ascertain if the functional outcome is improved in patients with ischemic wake-up stroke chosen by non-contrast CT if thrombolytic treatment with intravenous tenecteplase is administered within 4–5 h of awakening. The TWIST study involved 77 hospitals in 10 countries and was an investigator-initiated multicenter open-label randomized controlled experiment with blinded endpoint assessment. Patients were eligible if they were 18 or older, woke up with symptoms of acute ischaemic stroke, such as limb weakness, a National Institutes of Health Stroke Scale (NIHSS) score of 3 or higher, or aphasia, had a non-contrast CT of the head, and could receive tenecteplase within 4–5 hours of awakening.  Patients were allocated to receive either a single intravenous bolus of tenecteplase 0.25 mg per kg of body weight (maximum 25 mg) or control (no thrombolysis) based on a central, web-based, computer-generated randomization schedule (1:1). 

Research assistants were blinded to participants’ treatment assignments when they called them 90 days later to perform follow-up interviews. Upon admission to the hospital, clinical evaluations were conducted on Day 1 (for baseline purposes) and on Day 7 (or at discharge, whichever occurred first). In the study’s primary analysis, the 90-day functional outcome on the modified Rankin Scale (mRS) was analyzed with intention-to-treat population ordinal logistic regression. About 578 out of the required 600 individuals were enrolled between June 12, 2017, and September 30, 2021. (288 randomly assigned to the tenecteplase group and 290 to the control group [intention-to-treat population]). Participants’ median ages ranged from 737 to 811. Out of the total of 578 people, 332 (57%) were male and 246 (43%) were female. 

According to the modified Rankin Scale (mRS) at 90 days, tenecteplase treatment was not related with better functional outcome. (Adjusted OR = 1.18; 95% CI = 0.88-1.58; p = 0.27). There was no statistically significant difference in the 90-day mortality rate between the tenecteplase and control groups (28 patients (10%) in the tenecteplase group and 23 patients (8%) in the control group; adjusted HR 1.29, 95% CI 0.74-2.26; P=0.37). About 6 patients in the tenecteplase group (2%) and 3 patients in the control group (1%) experienced symptomatic intracranial haemorrhage (adjusted OR 217, 95% CI 053-887; P=028), while 33 patients in the tenecteplase group (11%) and 30 patients in the control group (10%) experienced any intracranial haemorrhage (adjusted OR 114). Treatment with tenecteplase was not related with improved functional outcome at 90 days in patients with wake-up stroke who were chosen using non-contrast CT. Previous trials of wake-up stroke patients screened with sophisticated imaging have shown that the number of symptomatic haemorrhages and any intracranial haemorrhages in both therapy groups is comparable. Patients identified using non-contrast CT do not currently have sufficient evidence to warrant treatment with tenecteplase.

Source: sciencedirect.com/science/article/abs/pii/S1474442222004847



Source link

Advertisement Banner
Previous Post

Signs, Symptoms, and Treatment of Aspiration Pneumonia

Next Post

Give Him a Hand – No, Really – The Health Care Blog

Related Posts

News

QA AND Advocacy: How Pediatricians Can Improve LGBTQ Mental Healthcare

October 3, 2023
News

Simplified Assessment Tool Predicts Psoriasis Severity

October 2, 2023
News

Glucagon-like peptide-1 receptor agonists exhibit weight loss effects in non-diabetic patients with obesity

October 1, 2023
News

#VisualAbstract: Complete or Culprit-Only Percutaneous Coronary Intervention in Older Patients with Myocardial Infarction

September 30, 2023
News

Causal Impact of Circulating Proteome on Osteoarthritis Traits

September 29, 2023
News

Surprising Phacodonesis Risk in Pseudoexfoliation Patients During Cataract Surgery

September 28, 2023
Next Post

Give Him a Hand – No, Really – The Health Care Blog

Recommended

Does Airway Protection Prevent Acute Respiratory Failure?

6 months ago

QA AND Advocacy: How Pediatricians Can Improve LGBTQ Mental Healthcare

19 hours ago

Validation of Bladder Health Scales and Functional Indices for Women’s Research on Bladder Function

3 months ago

The Pitfalls of Stainless-Steel Commercial Sinks

11 months ago

How to Recognize Respiratory Emergencies Before They Happen

6 months ago

© Doctors News Hubb All rights reserved.

Use of these names, logos, and brands does not imply endorsement unless specified. By using this site, you agree to the Privacy Policy and Terms & Conditions.

Navigate Site

  • Home
  • News
  • Healthcare
  • Public Health
  • Paramedic
  • Nursing
  • Contact Us

Newsletter Sign Up.

No Result
View All Result
  • Home
  • News
  • Healthcare
  • Public Health
  • Paramedic
  • Nursing
  • Contact Us

© 2022 Doctors News Hubb All rights reserved.